| 2024/04/10 17:30:53 | |
|---|---|
| Price | |
| 534.821 CHF | |
| Difference | -1.40% (-7.58) |
General attributes
| ISIN | CH0013841017 |
| Symbol | LONN |
| Exchange | London Stock Exchange |
| Currency | CHF |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 39,147 EUR |
| Benchmark | SWISS MARKET INDEX |
Market data
| Bid (Bid size) | 429.20 CHF (11) |
| Ask (Ask size) | 508.40 CHF (3) |
| Open | 532.00 CHF |
| High | 534.821 CHF |
| Low | 531.90 CHF |
| Close (prev. day) | 542.40 CHF |
| VWAP | 533.947511 CHF |
| Volume (pcs) | 4,400 |
| Trading volume | 2,349,369.05 |
| Number of trades | 3 |
| Last size | 3,050 |
Futures and Options
| Related Futures | 30 |
| Related Options | - |
PDF Downloads
| Company report: LONZA GROUP AG |  |
Add Benchmark:
Recent research
| Date | Headline | Download | |
| 2024/04/03 |
|
Global Equity Ratings |
|
| 2024/03/13 |
|
Global Equity Ratings |
|
| 2024/02/22 |
|
Global Equity Ratings |
|
| 2024/02/14 |
|
Global Equity Ratings |
|
| 2024/01/23 |
|
Global Equity Ratings |
|
| 2024/04/10 17:30:53 | |
|---|---|
| Price | |
| 534.821 CHF | |
| Difference | -1.40% (-7.58) |
General attributes
| ISIN | CH0013841017 |
| Symbol | LONN |
| Exchange | London Stock Exchange |
| Currency | CHF |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 39,147 EUR |
| Benchmark | SWISS MARKET INDEX |
Market data
| Bid (Bid size) | 429.20 CHF (11) |
| Ask (Ask size) | 508.40 CHF (3) |
| Open | 532.00 CHF |
| High | 534.821 CHF |
| Low | 531.90 CHF |
| Close (prev. day) | 542.40 CHF |
| VWAP | 533.947511 CHF |
| Volume (pcs) | 4,400 |
| Trading volume | 2,349,369.05 |
| Number of trades | 3 |
| Last size | 3,050 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | - | - | - |
| Perf (abs.) | - | - | - |
| Beta | 1.61 | 1.63 | 1.42 |
| Volatility | 26.79 | 36.10 | 30.67 |
Add Benchmark:
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 534.821 CHF (902) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 514.500 CHF (1,608) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 422.177 CHF (4,307) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 466.493 CHF (5,032) |
| YTD High | date | 556.000 CHF (2024/04/08) |
| YTD Low | date | 343.500 CHF (2024/01/08) |
| 52 Weeks High | date | 600.899 CHF (2023/06/06) |
| 52 Weeks Low | date | 310.123 CHF (2023/10/31) |
All listings for LONZA GROUP AG
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Singapore Exchange | 2011/10/21 | 09:51 | 74.0753 SGD | 0.00 | 1 |
| SIX Swiss Exchange | 2024/04/16 | 17:30 | 526.20 CHF | 103.00 | 5,582 |
| London Stock Exchange | 2024/04/10 | 17:30 | 534.821 CHF | 2.35 | 3 |
| Hamburg | 2019/06/28 | 08:01 | 291.30 EUR | 0.00 | 2 |
| Frankfurt | 2019/06/28 | 15:56 | 293.90 EUR | 0.02 | 4 |
| FINRA other OTC Issues | 2024/04/16 | 17:16 | 572.535 USD | 0.01 | 4 |
| Duesseldorf | 2019/06/28 | 08:11 | 291.20 EUR | 0.00 | 2 |
| Berlin | 2019/06/28 | 18:45 | 296.90 EUR | 0.00 | 14 |
| BX Swiss | 2024/04/16 | 18:00 | 524.90 CHF | 0.00 | 2 |
Company Logo
Contact Details
| LONZA GROUP AG |
| - - |
| Muenchensteinerstrasse 38 - 4002 Basel |
| Telefon: +41-61-316-81-11 |
| Fax: +41-61-316-91-11 |
| E-mail: media@lonza.com |
PDF Downloads
| Company report: LONZA GROUP AG | |
Company Profile
Lonza Group AG is engaged in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment offers small molecule drug substances and intermediates related services. The Cell and Gene segment includes the Cell and Gene Technologies and Bioscience businesses. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland. |
Members of Management Board
| Pierre-Alain Ruffieux | Chairman of Managing Board |
| Caroline Barth | Member of Executive Committee |
| Claude Dartiguelongue | Member of Executive Committee |
| Gordon Bates | Member of Executive Committee |
| Jean-Christophe Hyvert | Member of Executive Committee |
| Philippe Deecke | Member of Executive Committee |
| Stefan Stoffel | Member of Executive Committee |
Board of directors
| Angelica Kohlmann | Member of the administrative board |
| Marion Helmes | Member of the administrative board |
| Olivier Verscheure | Member of the administrative board |
| Roger Nitsch | Member of the administrative board |
| Barbara Richmond | Member of the administrative board |
| Christoph Mäder | Member of the administrative board |
| Jürgen B. Steinemann | Member of the administrative board |